Fibromyalgia is not a musculoskeletal disease in the traditional sense. Although it causes widespread muscle pain and was historically classified alongside conditions like arthritis, the weight of evidence points to it as a disorder of the nervous system, specifically how the brain and spinal cord process pain signals. The muscles themselves show no consistent damage or inflammation that would explain the severity of symptoms.
Why the Classification Has Shifted
For decades, fibromyalgia sat squarely in the rheumatology world. Rheumatologists diagnosed it, patients had muscle pain, and it seemed to belong alongside other musculoskeletal conditions. But as researchers looked more closely at what was actually happening in the body, the picture changed. Muscle biopsies from fibromyalgia patients show, at most, minor and inconsistent abnormalities. One study examining 77 biopsies from 57 patients found that more than half were normal or borderline, and the changes that did appear (small signs of degeneration or inflammation) weren’t reliable enough to serve as a diagnostic marker. Capillary density and muscle fiber composition looked the same in patients and healthy controls.
In the World Health Organization’s current disease classification system (ICD-11), fibromyalgia is coded as MG30 under “chronic pain,” rather than being grouped with diseases that damage joints, bones, or muscles. This reflects a growing consensus: the pain is real, but it originates from how the nervous system handles signals rather than from structural problems in the muscles or joints.
What’s Actually Happening in the Body
The dominant explanation for fibromyalgia pain is a concept called central sensitization. In simple terms, the volume knob for pain in the brain and spinal cord gets turned up. Signals that would normally register as mild discomfort, or not register at all, get amplified into significant pain. This type of pain has its own clinical name: nociplastic pain, meaning pain that arises from altered processing in the nervous system without clear evidence of tissue damage or nerve injury.
Brain imaging studies support this. When researchers compared resting brain scans of fibromyalgia patients to healthy controls, they found that patients had stronger-than-normal connections between pain-processing regions (particularly the insular cortex) and other brain networks. The stronger these connections were, the more intense the patient’s spontaneous pain at the time of the scan. In healthy people, these same brain networks behave differently, deactivating during certain tasks in ways that fibromyalgia patients’ brains do not.
There is also a competing theory that deserves mention. Some researchers argue that the process starts in the peripheral nervous system, specifically in clusters of nerve cells near the spine called dorsal root ganglia, and that central sensitization is a downstream effect rather than the root cause. Under this view, fibromyalgia would be a stress-triggered neuropathic pain condition. Either way, both camps place the problem in the nervous system rather than in the muscles.
How Fibromyalgia Differs From True Musculoskeletal Pain
One useful comparison is between fibromyalgia and myofascial pain syndrome, a condition that genuinely originates in muscle tissue. In myofascial pain, there are localized “trigger points” in tight bands of muscle. Pressing on them produces a jump response and sends pain radiating to a predictable area. The pain stays regional.
Fibromyalgia works differently. The tender areas are generalized rather than localized, spread across the body rather than concentrated in a few muscles. Pressing on them doesn’t produce the same jump response or referred pain pattern. And the condition comes packaged with symptoms that have nothing to do with muscles: persistent fatigue, unrefreshing sleep, cognitive difficulties (often called “fibro fog”), headaches, irritable bowel symptoms, and depression. A purely musculoskeletal condition wouldn’t produce that constellation of problems.
How Fibromyalgia Is Diagnosed
There is no blood test or imaging scan that confirms fibromyalgia. Diagnosis relies on a standardized scoring system that captures the breadth of symptoms. Doctors assess two things: how widespread the pain is (scored across 19 body areas) and how severe a set of core symptoms are, including fatigue, waking unrefreshed, and cognitive problems, plus whether headaches, abdominal pain, or depression have been present over the previous six months.
A diagnosis typically requires either a widespread pain score of 7 or higher combined with a symptom severity score of at least 5, or a pain score between 4 and 6 with a symptom severity score of 9 or higher. The criteria deliberately capture the full picture of the condition rather than focusing on pain alone, which reflects its nature as a central processing disorder rather than a localized tissue problem.
The Overlap With Rheumatic Diseases
One reason fibromyalgia gets confused with musculoskeletal disease is that it frequently shows up alongside genuine musculoskeletal conditions. About 6.6% of people with rheumatoid arthritis also meet criteria for fibromyalgia. The overlap is even higher in lupus (13.4%), ankylosing spondylitis (12.6%), and Sjögren’s syndrome (12%). In one study, 25% of vasculitis patients also had fibromyalgia.
This overlap creates a clinical challenge. When someone with rheumatoid arthritis also develops fibromyalgia, increasing the dose of anti-inflammatory medication won’t help the fibromyalgia symptoms because those symptoms aren’t driven by inflammation. Recognizing that both conditions are present, and that they require different management approaches, is essential for effective treatment.
Who Gets Fibromyalgia
Globally, fibromyalgia affects roughly 2% to 8% of the population, with an average prevalence around 2.7%. Women are affected about three times as often as men overall, though in clinical settings the disparity can be even wider, with women seven to nine times more likely to receive a diagnosis. Symptoms most commonly appear between the ages of 30 and 50. Prevalence varies considerably by region, from as low as 0.2% in Venezuela to as high as 6.4% in the United States.
How It’s Treated
The treatment approach for fibromyalgia further confirms its neurological nature. The three FDA-approved medications for the condition all target the nervous system. One is an anti-seizure drug that calms overactive nerve signaling. The other two are antidepressants that increase levels of serotonin and norepinephrine, neurotransmitters involved in the body’s pain-dampening pathways. None of them are anti-inflammatory drugs or muscle relaxants, the kinds of medications you’d use for a musculoskeletal problem.
Exercise is one of the most consistently supported interventions, but it requires a different mindset than typical fitness training. The key is starting at a level well below what provokes a pain flare and increasing gradually. Aerobic exercise, strength training, and flexibility work can all help, but the intensity and duration need to be tailored to individual pain tolerance. Pushing too hard too fast tends to backfire, triggering post-exertion pain that can set people back days. Many people with fibromyalgia find that consistent, moderate activity over weeks and months gradually reduces their baseline pain and improves sleep and energy levels.
Cognitive behavioral therapy and stress-management techniques also play a role, which makes sense given the strong connection between stress, nervous system regulation, and fibromyalgia symptoms. The most effective treatment plans typically combine medication, graduated exercise, and psychological strategies rather than relying on any single approach.